Want to see CH:PPGN full AI Analyst Report?
PPGN Stock Chart & Stats
CHF29.80
CHF1.30(6.77%)
At close: 4:00 PM EST
CHF29.80
CHF1.30(6.77%)
Day’s Range― - ―
52-Week RangeCHF20.10 - CHF50.10
Previous CloseN/A
Volume22.87K
Average Volume (3M)34.07K
Market Cap
CHF1.56B
Enterprise ValueCHF913.55
Total Cash (Recent Filing)CHF74.53M
Total Debt (Recent Filing)CHF130.46M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 13, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF40.50Price Target Upside35.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.79
Revenue Forecast (FY)CHF490.04M
Bulls Say, Bears Say
Bulls Say
CDMO Specialization & Multi-site GMP CapacityA focused CDMO model for peptides/oligonucleotides with multi-site GMP manufacturing is a durable competitive strength. It supports long-term contract wins, scale-up continuity, and regulatory compliance, enabling recurring commercial-supply revenues and higher switching costs for customers.
Consistent Revenue Growth And Improving Operating Cash FlowSteady top-line growth combined with improving operating cash flow across 2024–2025 indicates the business can grow volumes while generating operating liquidity. That durability helps fund working capital and reinvestment for capacity, reducing reliance on short-term financing over a multi-quarter horizon.
Reasonable Balance Sheet LeverageModerate debt-to-equity (~0.26–0.30) and a sizable equity base provide financial flexibility to fund capital-intensive capacity and development projects. This capital structure supports resilience to cyclical demand swings and lowers near-term refinancing pressure versus highly leveraged peers.
Bears Say
Persistent Net LossesSustained net losses across multiple years erode retained earnings and constrain the company's ability to self-fund growth. Over months to quarters this limits free capital for strategic investments, raises the likelihood of external financing or dilution, and weighs on long-term return generation.
Free Cash Flow VolatilityMaterial FCF swings and a sharp negative reading in 2025 signal uneven conversion of operating profits into investable cash. Persistent volatility reduces runway for capex and working-capital needs, increasing the chance of external funding and raising execution risk for multi-period capacity expansions.
Margin Compression And Weak Earnings ProfileSharp margin compression versus earlier peaks implies competitive or cost pressures that can persist. Even with improving EBIT, negative net income and compressed margins reduce the company's ability to rebuild profitability cushions, making long-term returns sensitive to pricing and input-cost trends.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF20.10 and its highest was CHF50.10 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.56B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Aug 13, 2026 which is in 27 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Mar 12, 2026. The company reported CHF0.152 earnings per share for the quarter, missing the consensus estimate of CHF0.268 by -CHF0.116.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.06.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.152 in its last earnings report, missing expectations of CHF0.268. Following the earnings report the stock price went up 8.776%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF40.50
▲(35.91% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―